Assessment of QT liabilities in drug development.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. 1, doi. 10.1007/s10565-006-0141-x
- By:
- Publication type:
- Article
Works matching IS 0742-2091 AND VI 23 AND IP 1 AND DT 2007
Results: 6
1
2
Protectors against doxorubicin-induced cardiotoxicity: Flavonoids.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. 39, doi. 10.1007/s10565-006-0139-4
- By:
- Publication type:
- Article
3
Foreword.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. v, doi. 10.1007/s10565-006-0889-z
- By:
- Publication type:
- Article
4
Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. 27, doi. 10.1007/s10565-006-0142-9
- By:
- Publication type:
- Article
5
Adriamycin-induced oxidative mitochondrial cardiotoxicity.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. 15, doi. 10.1007/s10565-006-0140-y
- By:
- Publication type:
- Article
6
In vitro modeling of the structure–activity determinants of anthracycline cardiotoxicity.
- Published in:
- Cell Biology & Toxicology, 2007, v. 23, n. 1, p. 49
- By:
- Publication type:
- Article